Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 31 - Medicinal preparations containing organic active ingredients
Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
03/2010
03/04/2010US20100055171 Pharmaceutical Formulation Comprising Donepezil
03/04/2010US20100055169 Cationic lipids and uses thereof
03/04/2010US20100055168 Cationic lipids and uses thereof
03/04/2010US20100055165 Liposomal gel phthalocyanine preparation for photodynamic therapy of tumors and its manufacturing
03/04/2010US20100055164 Synthetic lung surfactant and use thereof
03/04/2010US20100055163 Formulation of natural triterpenes and biophenols obtained from the genus olea in liposomes
03/04/2010US20100055160 Analgesic anti-inflammatory patches for topical use
03/04/2010US20100055159 Percutaneous preparations
03/04/2010US20100055158 Environmentally Activated Compositions, Articles and Methods
03/04/2010US20100055152 Antihistamine and antihistamine-like nasal application, products, and method
03/04/2010US20100055145 Stent coatings for reducing late stent thrombosis
03/04/2010US20100055137 Microemulsion & sub-micron emulsion process & compositions
03/04/2010US20100055133 Pharmaceutical compositions
03/04/2010US20100055116 Methods and Compositions for Targeting c-Rel
03/04/2010US20100055113 Cellular receptor for antiproliferative factor
03/04/2010US20100055108 Drug for treating gastric cancer
03/04/2010US20100055105 Novel Isolated And Purified Strains Of Chikungunya Virus And Polynucleotides And Polypetide Sequences, Diagnostic And Immunogenical Uses Thereof
03/04/2010US20100055100 Monitoring treatment of cancer patients with drugs targeting EGFR pathway using mass spectrometry of patient samples
03/04/2010US20100055094 Pharmaceutical combinations of 1-cyclopropyl-3- [3-(5-m0rphoolin-4-yl-methyl-1h-benzoimidazol-2-yl)- lh-1-pyrazol-4-yl]- urea
03/04/2010US20100055093 Pan-cell surface receptor-specific therapeutics
03/04/2010US20100055090 2-aminothiazole-4-carboxylic amides as protein kinase inhibitors
03/04/2010US20100055089 Methods for Inhibition of Lymphangiogenesis and Tumor Metastasis
03/04/2010US20100055086 Antimicrobial Flush Solutions
03/04/2010US20100055081 Long-lasting absorption of flavonoids
03/04/2010US20100055077 Methods for increasing and mobilizing hematopoietic stem cells
03/04/2010US20100055073 Treatment of pervasive developmental disorders
03/04/2010US20100055072 2-oxo-1,2-dihydro-quinoline modulators of immune function
03/04/2010US20100055071 Anti-Viral Compounds
03/04/2010US20100055069 Hpv-18-based papillomavirus vaccines
03/04/2010US20100055067 Perfluorocarbon conjugate as a blood substitute
03/04/2010US20100055066 Agent for prophylactic and/or therapeutic treatment of diabetes
03/04/2010US20100055065 Agent for inhibiting production of hepatitis c virus and its use
03/04/2010US20100055056 Agent for improving permeation of a drug into a nail and an external treating agent containing the same
03/04/2010US20100055055 Topical formulations of tellurium-containing compounds
03/04/2010US20100055053 Combinations for oral compositions, their preparation and use
03/04/2010US20100055048 Acute treatment of headache with phenothiazine antipsychotics
03/04/2010US20100055047 Methods for treating bronchial premalignancy and lung cancer
03/04/2010US20100055046 Composition and method for treating colds
03/04/2010US20100055037 Treatment, prevention, and reversal of alcohol-induced brain disease
03/04/2010US20100055033 Antibody compositions and methods for treatment of neoplastic disease
03/04/2010US20100051461 Poly and Copolyn(N-Vinylamide)s and their use in Capillary Electrophoresis
03/04/2010DE202009013422U1 Astaxanthin Astaxanthin
03/04/2010DE202008017680U1 Zubereitungen mit Hagebuttenextrakten Preparations with rosehip extracts
03/04/2010DE102008045339A1 Pharmazeutisches Pellet Pharmaceutical pellet
03/04/2010DE102008039734A1 Stabilisierung von Zellen durch ionische Flüssigkeiten Stabilization of cells by ionic liquids
03/04/2010CA2767961A1 Method of treating organophosphorous poisoning
03/04/2010CA2738328A1 Immunomodulating activities
03/04/2010CA2735776A1 Method for obtaining oligonucleotide aptamers and uses thereof
03/04/2010CA2735768A1 Novel piperidine-4-acetamide derivatives and their use as monoamine neurotransmitter re-uptake inhibitors
03/04/2010CA2735766A1 Novel piperidine-propionamide derivatives and their use as monoamine neurotransmitter re-uptake inhibitors
03/04/2010CA2735730A1 2,4-diaminopyrimidine compound
03/04/2010CA2735549A1 Substituted triazolo-pyridazine derivatives
03/04/2010CA2735497A1 New compounds suitable as precursors to compounds that are useful for imaging amyloid deposits
03/04/2010CA2735460A1 Novel anti-arrhythmia agent
03/04/2010CA2735439A1 Analysis of hcv genotypes
03/04/2010CA2735426A1 New 5-aminolevulinic acid prodrugs for use in photodynamic therapy and photodynamic diagnosis
03/04/2010CA2735421A1 Delivery of a cd40 agonist to a tumor draining lymph node of a subject
03/04/2010CA2735419A1 Compound signamycin, method for producing the same, and use of the same
03/04/2010CA2735413A1 Microparticles
03/04/2010CA2735373A1 Novel urea and thiourea derivatives
03/04/2010CA2735361A1 Thienopyrimidines for pharmaceutical compositions
03/04/2010CA2735286A1 Fused pyrrolidino-cyclopropane derivatives as selective 11-beta-hydroxysteroid dehydrogenase type 1 inhibitors
03/04/2010CA2735206A1 Pharmaceutical composition comprising n-[3-chloro-4-[(3-fluorophenyl)methoxy]phenyl]-6-[5[[[2-(methylsulfonyl)ethyl]amino]methyl]-2-furyl]-4-quinazolinamine
03/04/2010CA2735205A1 Pharmaceutical composition comprising n-[3-chloro-4-[(3- fluorophenyl)methoxy]phenyl]-6-[5[[[2-(methylsulfonyl)ethyl]amino]methyl]-2-furyl]-4- quinazolinamine
03/04/2010CA2735204A1 Aryl- and heteroarylcarbonyl derivatives of substituted nortropanes, medicaments containing such compounds and their use
03/04/2010CA2735177A1 Saturated bicyclic heterocyclic derivatives as smo antagonists
03/04/2010CA2735162A1 Pyrrole compounds
03/04/2010CA2735158A1 Compositions and methods of treating amyloid disease
03/04/2010CA2735118A1 Butyrylcholinesterase ligands as diagnostic tools and treatment for diseases of the nervous system
03/04/2010CA2735084A1 Novel polymorphs of sunitinib and processes for their preparation
03/04/2010CA2734981A1 Oxotetrahydrofuran-2-yl-benzimidazole derivative
03/04/2010CA2734979A1 Syngr4 for target genes of cancer therapy and diagnosis
03/04/2010CA2734965A1 Novel crystalline form and processes for its preparation
03/04/2010CA2734551A1 Pyridine derivatives as vegfr-2 receptor and protein tyrosine kinase inhibitors
03/04/2010CA2733795A1 Dioxa-bicyclo[3.2.1.]octane-2,3,4-triol derivatives
03/04/2010CA2733661A1 1-(4-ureidobenzoyl)piperazine derivatives
03/04/2010CA2733648A1 Novel pyrrole derivative having, as substituents, ureide group, aminocarbonyl group and bicyclic group which may have substituent
03/04/2010CA2733548A1 Formulations of canfosfamide and their preparation
03/04/2010CA2731442A1 Substituted aminothiazole derivatives, pharmaceutical compositions, and methods of use
03/04/2010CA2726234A1 Antihistamine and antihistamine-like nasal application, products, and method
03/04/2010CA2724766A1 Use of prebiotic galacto-oligosaccharides in the treatment of intestinal inflammation
03/04/2010CA2697993A1 Methods of enhancing adjuvanticity of vaccine compositions
03/03/2010EP2159286A1 Method for obtaining oligonucleotide aptamers and uses thereof
03/03/2010EP2159230A1 Anti-TNF antibodies, compositions, methods and uses
03/03/2010EP2159225A1 Gemifloxacin process and polymorphs
03/03/2010EP2159224A1 Bromo-phenyl substituted thiazolyl dihydropyrimidines
03/03/2010EP2159223A2 6 -acyloxy- 7-meth0xy- 2, 2 -dimethylchromane compounds and their use as pigmentation-regulators
03/03/2010EP2159221A1 Glucagon receptor antagonists, preparation and therapeutic uses
03/03/2010EP2159220A1 Organic compounds
03/03/2010EP2159216A1 Ih - Modulators
03/03/2010EP2158915A1 Acylglycerophospholipides for treating symptoms accompanying cancer
03/03/2010EP2158914A2 Use of estriol in low doses
03/03/2010EP2158913A1 Pharmaceutical composition comprising N-[3-chhloro-4-[(3-fluorophenyl)methoxy]phenyl]6-(5[[[2-(methylsulfonyl)ethyl]amino]methyl]-2-furyl]-4-quinazolinamine
03/03/2010EP2158912A1 Pharmaceutical composition comprising N-[3-chhloro-4-[3-fluorophenyl)methoxy)phenyl]6-[5[[[2-(methylsulfonyl)ethyl]amino]methyl]-2-furyl]-4-quinazolinamine
03/03/2010EP2158911A1 Stable pharmaceutical formulations of montelukast sodium
03/03/2010EP2158910A1 Use of neurokinin antagonists in the treatment of urinary incontinence
03/03/2010EP2158909A1 Combinations of vasoactive agents, their use in the pharmaceutical and cosmetic field, and formulations containing them
03/03/2010EP2158907A2 A composition for use as a medicament for topical application to skin
03/03/2010EP2158906A1 Composition for the treatment of alopecia
03/03/2010EP2158905A2 Composition for the Transdermal Delivery of Fentanyl
1 ... 2363 2364 2365 2366 2367 2368 2369 2370 2371 2372 2373 2374 2375 2376 2377 2378 2379 2380 2381 2382 2383 ... 7860